正在加载视频...

视频加载失败

加载此视频时出现问题。这可能是由于临时网络问题，或视频可能不可用。

In low-risk patients with MI and early complete revascularization, stopping aspirin after 1 month and continuing P2Y12 monotherapy was noninferior to dual antiplatelet therapy for ischemic outcomes and led to reduced bleeding at 1 year. Read the full TARGET-FIRST trial results in the Original Article “Early Discontinuation of Aspirin... show more

NEJM

1,040,073 subscribers

32,438 次观看 • 10 个月前 •via X (Twitter)

Anya Rossi• Live Now

Private livecam show

4 条评论

WILLIL 的头像

WILLIL10 个月前

@grok explain please

Astra 的头像

Astra10 个月前

Nice to see more data for shorter DAPT in truly low risk MI after PCI. This is good because it trades a drug with modest ischemic benefit for a clear reduction in bleeding, simplifies the regimen to one pill instead of two, and probably improves adherence and quality of life. The next step is turning the TARGET-FIRST phenotype into something clinicians can actually recognize in real time so appropriate patients stop aspirin early instead of sitting on 12 months of DAPT by default.

Hira Ali Cardiactech🫀🩺 的头像

Hira Ali Cardiactech🫀🩺10 个月前

Impressive findings! Early aspirin discontinuation in low-risk MI patients could truly change post-PCI practice. Excited to see how this reshapes guidelines.

Andrea 的头像

Andrea10 个月前

Anyway looking at the graph it seems that the benefit extend until about 6 months(1+5).

相关视频

In the phase 3 OCEANIC-STROKE trial involving patients with noncardioembolic ischemic stroke or high-risk TIA, asundexian added to antiplatelet therapy led to a lower risk of ischemic stroke without increasing major bleeding. Full trial results and Research Summary:

In the phase 3 OCEANIC-STROKE trial involving patients with noncardioembolic ischemic stroke or high-risk TIA, asundexian added to antiplatelet therapy led to a lower risk of ischemic stroke without increasing major bleeding. Full trial results and Research Summary:

NEJM

12,392 次观看 • 5 个月前

Among patients with atrial fibrillation at high risk for stroke and bleeding, left atrial appendage closure was not noninferior to medical therapy in reducing the risk of stroke, embolism, major bleeding, or death at 3 years. Full CLOSURE-AF trial results and Research Summary: #Cardiology #AFib

Among patients with atrial fibrillation at high risk for stroke and bleeding, left atrial appendage closure was not noninferior to medical therapy in reducing the risk of stroke, embolism, major bleeding, or death at 3 years. Full CLOSURE-AF trial results and Research Summary: #Cardiology #AFib

NEJM

15,621 次观看 • 6 个月前

In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period. Full COBRRA trial results and Research Summary:

In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period. Full COBRRA trial results and Research Summary:

NEJM

12,266 次观看 • 6 个月前

NEJM Editorial Fellow Minali Nigam, MD, shares the key results of the ORIENTAL-MeVO trial, which investigated whether endovascular thrombectomy for acute ischemic stroke improves functional outcomes in patients with medium-vessel occlusion and moderate-to-severe deficits. Read the full trial results:

NEJM Editorial Fellow Minali Nigam, MD, shares the key results of the ORIENTAL-MeVO trial, which investigated whether endovascular thrombectomy for acute ischemic stroke improves functional outcomes in patients with medium-vessel occlusion and moderate-to-severe deficits. Read the full trial results:

NEJM

16,994 次观看 • 2 个月前

Everything we have learned so far about the revascularization of non-culprit lesions in patients with acute myocardial infarction and multivessel disease... in 1 minute.

Everything we have learned so far about the revascularization of non-culprit lesions in patients with acute myocardial infarction and multivessel disease... in 1 minute.

Davide Capodanno

28,521 次观看 • 2 年前

Catheter-Directed PE Treatment: Does it Deliver? NEJM Clinician Editor-in-Chief Raja-Elie Abdulnour, MD (Raja-Elie Abdulnour), explains a trial recently published in NEJM that compared catheter-directed thrombolysis to anticoagulation alone for acute, intermediate-risk pulmonary embolism. Read the key results and comment from Michael E. Billington, MD: Visit to see What Matters Most This Week, including: 🫀 New ACC/AHA Guideline on Lipid Management and ASCVD Prevention 💊 Chronic Beta-Blocker Use in Low-Risk Patients after MI: Time to Re-Evaluate 🧠 Reducing the Risk of Recurrent Stroke in Patients with Left Ventricular Dysfunction 🎯 What's the Ideal LDL Target for Patients with Cardiovascular Disease?

Catheter-Directed PE Treatment: Does it Deliver? NEJM Clinician Editor-in-Chief Raja-Elie Abdulnour, MD (Raja-Elie Abdulnour), explains a trial recently published in NEJM that compared catheter-directed thrombolysis to anticoagulation alone for acute, intermediate-risk pulmonary embolism. Read the key results and comment from Michael E. Billington, MD: Visit to see What Matters Most This Week, including: 🫀 New ACC/AHA Guideline on Lipid Management and ASCVD Prevention 💊 Chronic Beta-Blocker Use in Low-Risk Patients after MI: Time to Re-Evaluate 🧠 Reducing the Risk of Recurrent Stroke in Patients with Left Ventricular Dysfunction 🎯 What's the Ideal LDL Target for Patients with Cardiovascular Disease?

NEJM

12,682 次观看 • 6 个月前

"Taking An Aspirin Everyday To Prevent A Heart Attack Is Wrong, Dangerous & Can Be Deadly." Dr Jack Wolfson, Cardiologist "A Daily Aspirin Is A Lie That's Been Fed To Us For Over 50 Years." "Aspirin Does Not Protect You Or Fix Your Damaged Arteries...It Just Makes You Bleed." Almost 30 million Americans take aspirin for primary or secondary prevention of cardiovascular disease (CVD) or colorectal cancer (CRC). For decades, low dose Aspirin has been prescribed to patients as primary prevention for patients at risk for CVD, but has now been withdrawn as a line of treatment or prevention. The most recent recommendations from the US Preventive Services Task Force (USPSTF) have abandoned the routine call for daily aspirin use because of the harms that daily low dose aspirin causes. Research From The ARRIVE, ASPREE & ASCEND Peer Reviewed Studies, Confirms That Daily Aspirin, Even Low Dose 'Baby Aspirin,' Is Harmful & Causes Major Bleeding: More than 46,000 adults were studied for multiple years on low dose enteric coated 100 mg aspirin & found significant major bleeding while also finding no benefit for cardiovascular disease. The causal factor of the increased risk of bleeding is aspirin inhibits platelet activity as a COX-1 inhibitor, which damages the protective layer of gastrointestinal mucosa, intracranial brain tissue & micro bleeding anemia. 1⃣ Increased risk of major bleeding: This includes gastrointestinal (GI) bleeding (e.g., ulcers, bleeding in the stomach or intestines) & intracranial hemorrhage (bleeding in the brain), which can be severe & life-threatening. 2⃣ Hemorrhagic stroke: Aspirin increases the risk of hemorrhagic strokes, where a blood vessel bursts in the brain. Bleeding events were 38% higher among participants who were taking aspirin daily, regardless of their gender, age, or cardiovascular risk. 3⃣ Anemia: The ASPREE trial, showed 20% increase in Anemia, characterized by low red blood cell counts & symptoms like fatigue & weakness. Slow micro bleeding anemia as low Hemoglobin iron & Ferritin levels plummeting to less than 45 mcg/L. 4⃣ Gastrointestinal damage: Aspirin, even at low doses, causes damage to the lining of the stomach & intestines, leading to erosions, ulcers & bleeding. Research participant data showed 60% had major GI bleeds as a result of a daily low dose aspirin. 👇ASCEND Aspirin Bleeding Risk Study👇 👇Daily Low Dose Aspirin Causes Anemia👇 👇ASPREE Low Dose Aspirin Causes GI Bleeding👇 Speaker: Dr Jack Wolfson, MD

"Taking An Aspirin Everyday To Prevent A Heart Attack Is Wrong, Dangerous & Can Be Deadly." Dr Jack Wolfson, Cardiologist "A Daily Aspirin Is A Lie That's Been Fed To Us For Over 50 Years." "Aspirin Does Not Protect You Or Fix Your Damaged Arteries...It Just Makes You Bleed." Almost 30 million Americans take aspirin for primary or secondary prevention of cardiovascular disease (CVD) or colorectal cancer (CRC). For decades, low dose Aspirin has been prescribed to patients as primary prevention for patients at risk for CVD, but has now been withdrawn as a line of treatment or prevention. The most recent recommendations from the US Preventive Services Task Force (USPSTF) have abandoned the routine call for daily aspirin use because of the harms that daily low dose aspirin causes. Research From The ARRIVE, ASPREE & ASCEND Peer Reviewed Studies, Confirms That Daily Aspirin, Even Low Dose 'Baby Aspirin,' Is Harmful & Causes Major Bleeding: More than 46,000 adults were studied for multiple years on low dose enteric coated 100 mg aspirin & found significant major bleeding while also finding no benefit for cardiovascular disease. The causal factor of the increased risk of bleeding is aspirin inhibits platelet activity as a COX-1 inhibitor, which damages the protective layer of gastrointestinal mucosa, intracranial brain tissue & micro bleeding anemia. 1⃣ Increased risk of major bleeding: This includes gastrointestinal (GI) bleeding (e.g., ulcers, bleeding in the stomach or intestines) & intracranial hemorrhage (bleeding in the brain), which can be severe & life-threatening. 2⃣ Hemorrhagic stroke: Aspirin increases the risk of hemorrhagic strokes, where a blood vessel bursts in the brain. Bleeding events were 38% higher among participants who were taking aspirin daily, regardless of their gender, age, or cardiovascular risk. 3⃣ Anemia: The ASPREE trial, showed 20% increase in Anemia, characterized by low red blood cell counts & symptoms like fatigue & weakness. Slow micro bleeding anemia as low Hemoglobin iron & Ferritin levels plummeting to less than 45 mcg/L. 4⃣ Gastrointestinal damage: Aspirin, even at low doses, causes damage to the lining of the stomach & intestines, leading to erosions, ulcers & bleeding. Research participant data showed 60% had major GI bleeds as a result of a daily low dose aspirin. 👇ASCEND Aspirin Bleeding Risk Study👇 👇Daily Low Dose Aspirin Causes Anemia👇 👇ASPREE Low Dose Aspirin Causes GI Bleeding👇 Speaker: Dr Jack Wolfson, MD

Valerie Anne Smith

209,973 次观看 • 1 年前

Our latest video in our partnership with Dr. Glaucomflecken summarizes the results of a trial that evaluated whether management of shock without early arterial catheterization is noninferior to the practice of early catheter insertion with regard to death from any cause at day 28. Read the full results for free:

Our latest video in our partnership with Dr. Glaucomflecken summarizes the results of a trial that evaluated whether management of shock without early arterial catheterization is noninferior to the practice of early catheter insertion with regard to death from any cause at day 28. Read the full results for free:

NEJM

47,918 次观看 • 9 个月前

In patients with atrial fibrillation and intermediate stroke risk, direct oral anticoagulation led to a lower risk of stroke, systemic embolism, major bleeding, or death from cardiovascular causes than no anticoagulation. Full SINGLE-AF trial results: #ESCCongress | European Society of Cardiology

In patients with atrial fibrillation and intermediate stroke risk, direct oral anticoagulation led to a lower risk of stroke, systemic embolism, major bleeding, or death from cardiovascular causes than no anticoagulation. Full SINGLE-AF trial results: #ESCCongress | European Society of Cardiology

NEJM

16,284 次观看 • 1 个月前

In high-risk localized prostate cancer, ADT plus apalutamide led to a pathological complete response or minimal residual disease and 5-year metastasis-free survival in a greater percentage of patients than ADT plus placebo. Full phase 3 PROTEUS trial results and Research Summary:

In high-risk localized prostate cancer, ADT plus apalutamide led to a pathological complete response or minimal residual disease and 5-year metastasis-free survival in a greater percentage of patients than ADT plus placebo. Full phase 3 PROTEUS trial results and Research Summary:

NEJM

28,964 次观看 • 2 个月前

Among patients with severe hypertriglyceridemia, treatment with olezarsen led to a significantly greater reduction in the triglyceride level at 6 months and in the incidence of acute pancreatitis than placebo. Read the full results of the CORE-TIMI 72a and CORE2-TIMI 72b trials:

Among patients with severe hypertriglyceridemia, treatment with olezarsen led to a significantly greater reduction in the triglyceride level at 6 months and in the incidence of acute pancreatitis than placebo. Read the full results of the CORE-TIMI 72a and CORE2-TIMI 72b trials:

NEJM

13,473 次观看 • 8 个月前

In a meta-analysis involving 17,801 patients with myocardial infarction and preserved LVEF (≥50%), beta-blockers did not reduce death, MI, or heart failure over a median 3.6 years of follow-up. Full trial results and Research Summary:

In a meta-analysis involving 17,801 patients with myocardial infarction and preserved LVEF (≥50%), beta-blockers did not reduce death, MI, or heart failure over a median 3.6 years of follow-up. Full trial results and Research Summary:

NEJM

25,407 次观看 • 8 个月前

This randomized #clinicaltrial demonstrated that adding low-dose intra-arterial alteplase after endovascular thrombectomy in acute ischemic #Stroke improved microvascular perfusion and functional outcomes compared with thrombectomy alone. Despite these findings, increased #mortality in the #alteplase group highlights the need for careful risk-benefit assessment when considering adjunctive pharmacologic strategies. 📖 Read the full article to learn more: 📹: Melanie Molina, MD MAS

This randomized #clinicaltrial demonstrated that adding low-dose intra-arterial alteplase after endovascular thrombectomy in acute ischemic #Stroke improved microvascular perfusion and functional outcomes compared with thrombectomy alone. Despite these findings, increased #mortality in the #alteplase group highlights the need for careful risk-benefit assessment when considering adjunctive pharmacologic strategies. 📖 Read the full article to learn more: 📹: Melanie Molina, MD MAS

JAMA

16,597 次观看 • 2 个月前

In a trial of patients with bifurcation lesions, main branch stenting and POT, ending the procedure with no further intervention was noninferior to POT-side-POT or kissing balloon inflation for myocardial injury or infarction, and less likely required a second stent. #EuroPCR

In a trial of patients with bifurcation lesions, main branch stenting and POT, ending the procedure with no further intervention was noninferior to POT-side-POT or kissing balloon inflation for myocardial injury or infarction, and less likely required a second stent. #EuroPCR

PCRonline 🫀

31,035 次观看 • 3 年前

What is the best oxygenation strategy for patients with acute hypoxemic respiratory failure? NEJM Editorial Fellow Katerina Lin, MD, shares the key results of a trial comparing high-flow to standard oxygen in respiratory failure. Read the full study at

What is the best oxygenation strategy for patients with acute hypoxemic respiratory failure? NEJM Editorial Fellow Katerina Lin, MD, shares the key results of a trial comparing high-flow to standard oxygen in respiratory failure. Read the full study at

NEJM

36,483 次观看 • 27 天前

In high-grade asymptomatic carotid stenosis, addition of stenting to medical therapy led to a lower risk of stroke over a 4-year period. Endarterectomy did not lead to a significant benefit. Full results of the CREST-2 trials and Research Summary:

In high-grade asymptomatic carotid stenosis, addition of stenting to medical therapy led to a lower risk of stroke over a 4-year period. Endarterectomy did not lead to a significant benefit. Full results of the CREST-2 trials and Research Summary:

NEJM

18,796 次观看 • 8 个月前

Our latest video in our partnership with Dr. Glaucomflecken summarizes the POTCAST trial, which assessed a strategy of actively increasing plasma potassium levels to the high-normal range in patients at high risk for ventricular arrhythmias. Read the full study for free:

Our latest video in our partnership with Dr. Glaucomflecken summarizes the POTCAST trial, which assessed a strategy of actively increasing plasma potassium levels to the high-normal range in patients at high risk for ventricular arrhythmias. Read the full study for free:

NEJM

89,852 次观看 • 8 个月前

In the latest video in our partnership with Dr. Glaucomflecken, the REGENCY trial investigating the efficacy and safety of obinutuzumab when added to standard therapy in patients with active proliferative lupus nephritis is explained. Access the article for free:

In the latest video in our partnership with Dr. Glaucomflecken, the REGENCY trial investigating the efficacy and safety of obinutuzumab when added to standard therapy in patients with active proliferative lupus nephritis is explained. Access the article for free:

NEJM

144,816 次观看 • 1 年前

In a 104-week trial involving patients with primary membranous nephropathy, the type II anti-CD20 antibody obinutuzumab was superior to the calcineurin inhibitor tacrolimus in inducing complete remission. Full phase 3 MAJESTY trial results and Research Summary:

In a 104-week trial involving patients with primary membranous nephropathy, the type II anti-CD20 antibody obinutuzumab was superior to the calcineurin inhibitor tacrolimus in inducing complete remission. Full phase 3 MAJESTY trial results and Research Summary:

NEJM

19,382 次观看 • 1 个月前